Orchestra Biomed Holdings, INC Form 4 insider transactions

Darren Sherman, President and COO of Orchestra BioMed Holdings, sold shares of common stock between September 4th and September 6th, 2024, to cover tax obligations associated with the vesting of restricted stock units.

David Hochman, CEO of Orchestra BioMed Holdings, recently purchased 2,500 shares of common stock at a price of $5.84 per share.

Director Mack John Prosper reports the acquisition of restricted stock units and stock options in Orchestra BioMed Holdings, Inc.

HSAC 2 Holdings, LLC reports a distribution of shares in Orchestra BioMed Holdings, Inc. to its members, resulting in a decreased direct ownership.

Director David P. Hochman increased his holdings in Orchestra BioMed Holdings, Inc. by purchasing 1,000 shares of common stock at $6.95 per share on June 25, 2024.

Director Pamela Ann Connealy of Orchestra BioMed Holdings, Inc. [OBIO] acquired stock options and restricted stock units on June 20, 2024.

Director Aryeh Jason acquired 5,376 shares of common stock and 17,068 stock options in Orchestra BioMed Holdings on June 20, 2024.

Director Eric A. Rose of Orchestra BioMed Holdings, Inc. reports acquisition of stock options and restricted stock units.

Director Eric S. Fain reports acquisition of common stock and stock options in Orchestra BioMed Holdings.

Director David Pacitti acquired 5,376 shares of common stock and 17,068 stock options in Orchestra BioMed Holdings on June 20, 2024.

William Reed Little, an executive at Orchestra BioMed Holdings, Inc., purchased 4,000 shares of common stock at $7 per share on May 30, 2024.

David P. Hochman, a director at Orchestra BioMed Holdings, filed an amendment to a previous Form 4 to correct transaction codes related to recent stock purchases.

Orchestra BioMed Holdings CEO David Hochman recently acquired additional shares of the company's common stock through direct purchases and trusts.

Yuval Mika, General Manager and Chief Technology Officer at Orchestra BioMed, reports the acquisition of restricted stock units and disposal of common stock.

Joshua Aiello, Principal Accounting Officer of Orchestra BioMed Holdings, acquired 42,000 stock options on May 8, 2024, with vesting occurring over the next three years.

George Papandreou, General Manager and Senior Vice President at Orchestra BioMed Holdings, received 33,000 stock options and 22,000 restricted stock units on May 8, 2024.

David P. Hochman, CEO and Chairperson of Orchestra BioMed Holdings, Inc., was granted 100,000 restricted stock units (RSUs) on May 8, 2024.

Darren Sherman, President and COO of Orchestra BioMed Holdings, was granted 176,667 restricted stock units (RSUs) on May 8, 2024, vesting over approximately three years.

William Reed Little, an executive at Orchestra BioMed Holdings, was granted 53,333 restricted stock units (RSUs) on May 8, 2024.

Andrew Lawrence Taylor, CFO of Orchestra BioMed Holdings, Inc., was granted 100,000 restricted stock units (RSUs) on May 8, 2024, vesting over approximately three years.

Director David Pacitti receives stock options and restricted stock units from Orchestra BioMed Holdings.